Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
14 pending office actions • 11 art units • 12 examiners • 0 of 14 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Kashiv Biosciences LLC has 15 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 12 distinct examiners and 11 distinct art units, indicating broad assignment across both examiners and technology units.
MCDERMOTT, JEANNIE is the busiest listed examiner, with 4 pending actions. That examiner represents the clearest point of concentration in the reported docket, although the remaining actions involve other examination relationships. Counsel can consider consistent handling for MCDERMOTT matters while maintaining separate strategies elsewhere.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (21%) |
| §102 only | 1 (7%) |
| Double-patenting only | 1 (7%) |
| Double-patenting + other | 2 (14%) |
| Multi-statute (no §101) | 7 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCDERMOTT, JEANNIE | 3 | 60.4% | +15.1% |
| REGLAS, GEORGIANA C | 1 | 39.2% | +33.4% |
| ROONEY, NORA MAUREEN | 1 | 60.5% | +23.4% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
| KINGDON, CATHY | 1 | 80.3% | +2.6% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| COOK, LISA V | 1 | 67.5% | +10.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | WILLIS, DOUGLAS M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19230884 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | MCDERMOTT, JEANNIE | 32d overdue |
| 18262318 | METHOD FOR SIZE BASED EVALUATION OF PANCREATIC PROTEIN MIXTURE | ROBINSON, HOPE A | 24d overdue |
| 19432904 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | MCDERMOTT, JEANNIE | — |
| 18696701 | AN IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN | KINGDON, CATHY | — |
| 18550920 | NOVEL FORMULATION OF FUSION PROTEIN | CHANDRA, GYAN | — |
| 17919171 | STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB | D' AMBROSIO, THEA | — |
| 17627477 | PROCESS FOR SEPARATION AND QUANTITATION OF PROTEINS USING CAPILLARY ELECTROPHORESIS | OSMAN, SOMMER YOUSEF | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17934950 | PROCESS FOR PREPARATION OF STABLE PROTEIN SOLUTION | COOK, LISA V | 59d overdue |
| 19230889 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | MCDERMOTT, JEANNIE | 35d overdue |
| 19230884 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | MCDERMOTT, JEANNIE | 32d overdue |
| 18262318 | METHOD FOR SIZE BASED EVALUATION OF PANCREATIC PROTEIN MIXTURE | ROBINSON, HOPE A | 24d overdue |
| 19432904 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | MCDERMOTT, JEANNIE | — |
| 19432924 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | REGLAS, GEORGIANA C | — |
| 19282184 | PROCESS OF PURIFICATION OF PROTEIN | ROONEY, NORA MAUREEN | — |
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | WILLIS, DOUGLAS M | — |
| Art Unit | Apps |
|---|---|
| 1776 | 2 |
| 1641 | 2 |
| 1624 | 2 |
| 1651 | 1 |
| 1777 | 1 |
| 1678 | 1 |
| 1663 | 1 |
| 1674 | 1 |
| 1652 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19432904 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | MCDERMOTT, JEANNIE | 1776 | §103§112Other | Non-Final OA | — | Pending | Dec 24, 2025 |
| 19432924 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | REGLAS, GEORGIANA C | 1651 | §102 | Final Rejection | — | Pending | Dec 24, 2025 |
| 19282184 | PROCESS OF PURIFICATION OF PROTEIN | ROONEY, NORA MAUREEN | 1641 | §112DP | Non-Final OA | — | Pending | Jul 28, 2025 |
| 19230884 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | MCDERMOTT, JEANNIE | 1777 | §103§112Other | Non-Final OA | 32d overdue | Pending | Jun 06, 2025 |
| 19230889 | AN IMPROVED PROCESS OF PURIFICATION OF PROTEIN | MCDERMOTT, JEANNIE | 1776 | §103Other | Non-Final OA | 35d overdue | Pending | Jun 06, 2025 |
| 18705711 | INJECTABLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF BREAST CANCER | WILLIS, DOUGLAS M | 1624 | §112DP | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18620649 | PROCESS FOR PURIFICATION OF PROTEIN | HAQ, SHAFIQUL | 1678 | §103 | Final Rejection | — | Pending | Mar 28, 2024 |
| 18696701 | AN IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN | KINGDON, CATHY | 1663 | §103§112Other | Final Rejection | — | Pending | Mar 28, 2024 |
| 18550920 | NOVEL FORMULATION OF FUSION PROTEIN | CHANDRA, GYAN | 1674 | §103§112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18262318 | METHOD FOR SIZE BASED EVALUATION OF PANCREATIC PROTEIN MIXTURE | ROBINSON, HOPE A | 1652 | §102§103§112 | Final Rejection | 24d overdue | Pending | Jul 20, 2023 |
| 17919171 | STABLE READY TO DILUTE FORMULATIONS OF CARFILZOMIB | D' AMBROSIO, THEA | 1654 | §103§112 | Non-Final OA | — | Pending | Oct 14, 2022 |
| 17934950 | PROCESS FOR PREPARATION OF STABLE PROTEIN SOLUTION | COOK, LISA V | 1641 | DP | Non-Final OA | 59d overdue | Pending | Sep 23, 2022 |
| 17627477 | PROCESS FOR SEPARATION AND QUANTITATION OF PROTEINS USING CAPILLARY ELECTROPHORESIS | OSMAN, SOMMER YOUSEF | 1794 | §103§112 | Non-Final OA | — | Pending | Jan 14, 2022 |
| 17058390 | PRODRUGS OF FULVESTRANT | MOORE, SUSANNA | 1624 | §103 | Final Rejection | 27d | Pending | Nov 24, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKashiv Biosciences LLC has 14 pending office actions as of October 2026, spread across 11 art units and 12 examiners.
Jeannie Mcdermott has the most, with 3 of Kashiv Biosciences LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
